MedTrace Logo

Buprenorphine Dose Adjustments and Gestational Age

NCT03028883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-11-21

No results posted yet for this study

Summary

In this retrospective cohort study, we plan to examine the relationship between buprenorphine dose adjustments, gestational age, urine buprenorphine levels and the rate of neonatal abstinence syndrome in opioid-maintained pregnant women

Conditions

  • Neonatal Abstinence Syndrome

Interventions

OTHER

Dose adjustments

Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine

Sponsors & Collaborators

  • St. Louis University

    lead OTHER

Principal Investigators

  • Jaye Shyken, MD · St. Louis University

Eligibility

Min Age
14 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-02
Primary Completion
2016-12-22
Completion
2016-12-22

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03028883 on ClinicalTrials.gov